Resolvins RvD1 and 17(R)-RvD1 alleviate signs of inflammation in a rat model of endometriosis

Abstract

Objective: To study the effects of two resolvins of D series, RvD1 and 17(R)-RvD1, on inflammatory signs associated with endometriosis (ENDO).

Design: In vivo research study.

Setting: Research laboratory.

Animal(s): Female Sprague-Dawley rats.

Intervention(s): Intravenous or intraperitoneal injections of RvD1 (300 ng/kg) or 17(R)-RvD1 (300 and 900 ng/kg) in rats with surgically induced ENDO.

Main outcome measure(s): Vascular permeability of ectopic endometrial growths was assessed by Evans Blue extravasation; vaginal hyperalgesia was assessed with telemetered visceromotor response.

Result(s): Both resolvins, but not vehicle, significantly decreased vascular permeability in ectopic endometrial tissue. 17(R)-RvD1 also significantly alleviated severity of vaginal hyperalgesia.

Conclusion(s): Our results suggest that RvD1 and 17(R)-RvD1 can be considered for further investigation of their therapeutic potential for treating ENDO.

Keywords: Proresolving lipid mediator; cyclo-oxygenase 2; docosahexaenoic acid; endometrium; hyperalgesia; omega-3 polyunsaturated fatty acid.